India · Delayed Price · Currency is INR CORONA Remedies Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw 15% YoY revenue growth and 24% YoY adjusted PAT growth, driven by strong chronic and semi-chronic therapy performance and strategic brand acquisitions. The company remains net cash positive, with robust return ratios and a stable outlook for mid-teen revenue and high-teen PAT growth.
-
Q1 FY 2027 saw 21.9% revenue growth and 30.1% PAT growth, driven by strong India business, robust volume and price gains, and leadership in chronic therapies. New hormone facility and brand expansion support long-term growth, with guidance maintained despite input cost risks.
-
Revenue and profit grew strongly in Q2 and H1 FY26, driven by chronic therapies and strategic acquisitions. Guidance targets 15% CAGR revenue and 20% PAT/EPS growth, with new launches and international expansion planned. ROE and ROCE remain robust.